Quick answer: Average human lifespan in developed nations has increased dramatically over the past century (from ~47 to ~77 years in the US), but “healthspan” — the years of vigorous, functional health — has not kept pace. An American who reaches age 65 now spends an average of 9–12 years with significant chronic disease burden before death (WHO data). The emerging science of longevity medicine addresses this gap: using biomarkers of biological aging (epigenetic clocks, telomere length, proteomics), pharmacological interventions with animal lifespan extension evidence (rapamycin, metformin, acarbose, senolytics), and evidence-based lifestyle interventions (caloric restriction mimetics, exercise physiology optimization, sleep architecture) to extend both lifespan and healthspan. This guide presents the complete state-of-the-art functional medicine longevity framework.
The Hallmarks of Aging: A Targetable Framework
López-Otín et al.’s landmark 2013 Cell paper identified 9 hallmarks of aging — recently expanded to 12 in their 2023 update — that collectively drive the biological aging process. These include: genomic instability (DNA damage accumulation), telomere attrition, epigenetic alterations (DNA methylation drift, histone modification dysregulation), loss of proteostasis (misfolded protein accumulation, impaired autophagy), deregulated nutrient sensing (mTOR, AMPK, IGF-1, sirtuins), mitochondrial dysfunction (mtDNA mutations, ETC inefficiency), cellular senescence (non-dividing but metabolically active “zombie cells” secreting SASP), stem cell exhaustion, and altered intercellular communication (chronic inflammation/”inflammaging”). Functional longevity medicine targets multiple hallmarks simultaneously — using polypharmacy of low-risk interventions rather than single high-dose approaches.
Epigenetic Age: Measuring Biological vs. Chronological Age
The discovery of epigenetic aging clocks by Steve Horvath (2013, Genome Biology) revolutionized aging biology: by measuring DNA methylation patterns at hundreds of specific CpG sites, his algorithm (“Horvath clock”) predicts chronological age from blood or tissue samples with extraordinary accuracy (<3.6 years MAE across 51 tissue types). More clinically valuable are "second-generation" clocks that predict mortality and health outcomes: GrimAge (Lu 2019, Aging) — the strongest predictor of lifespan, incorporating smoking/metabolic composite, outperforms chronological age for predicting time-to-death; PhenoAge (Levine 2018, Aging) — predicts biological age-related morbidity; DunedinPACE (Belsky 2022, eLife) — measures the pace of aging over time rather than a static snapshot, providing a rate-of-aging metric suitable for intervention trials.
Lifestyle interventions that reverse epigenetic age: Lu et al. (2019) found that a 24-component “comprehensive lifestyle program” (diet, exercise, sleep, relaxation, supplementation including methylated B vitamins, melatonin, green tea, probiotics) reversed GrimAge by 1.96 years in 8 weeks in men. Fitzgerald et al. (2021, Aging) — the first dietary RCT using epigenetic age as a primary outcome — found that 8 weeks of intensive diet + sleep + exercise + relaxation + supplementation reduced DunedinPACE biological age by 3.23 years vs. control. Weight loss through caloric restriction reduces epigenetic age (Wahl 2017). Mediterranean diet reverses PhenoAge by ~1.5 years. Exercise (Bonder 2017 — aerobic exercise significantly reduces epigenetic age in adipose tissue). These findings validate that biological aging is modifiable.
mTOR and AMPK: The Nutrient Sensing Longevity Pathways
The mTOR (mechanistic target of rapamycin) pathway is the master regulator of cellular growth and anabolism — activated by nutrients (amino acids, glucose), growth factors (insulin/IGF-1), and energy availability. mTOR activation drives: protein synthesis, cell growth, inhibition of autophagy (cellular recycling), and — when chronically overstimulated — contributes to cellular aging, cancer, neurodegeneration, and immune senescence. Caloric restriction (CR) — the most reproducible intervention to extend lifespan across species (35% CR extends median lifespan by 30–40% in rodents; CALERIE trial confirmed metabolic improvements in humans) — works primarily by reducing mTOR and insulin/IGF-1 signaling. Rapamycin (mTOR inhibitor) extends mouse lifespan by 9–14% even when started at equivalent human age of 60 (Harrison 2009, Nature). Matthew Kaeberlein and colleagues have documented rapamycin extending healthy lifespan in companion dogs — human trials ongoing. Intermittent fasting and TRE achieve CR-equivalent mTOR suppression through timed nutrient restriction without continuous caloric deficit.
AMPK (AMP-activated protein kinase) is the cellular energy sensor that activates when ATP:AMP ratio falls — mimicking the low-energy state that promotes longevity adaptations. AMPK activators: exercise (the primary physiological activator — each bout acutely raises muscle AMPK substantially), metformin (liver AMPK activation), berberine (AMPK agonist — comparable to metformin in multiple metabolic studies), resveratrol (indirect AMPK activation via SIRT1-LKB1 axis), and caloric restriction. AMPK activation promotes: mitochondrial biogenesis (PGC-1α), autophagy (mTOR suppression), fat oxidation, and anti-inflammatory signaling. The AMPK-mTOR balance is a core longevity axis — favoring AMPK activation (through exercise, fasting, and pharmacological mimetics) over chronic mTOR stimulation (excess calories, sedentary behavior, excess mTOR-stimulating protein intake) is a primary functional longevity strategy.
Senolytics and Senomorphics: Targeting Cellular Senescence
Cellular senescence — the accumulation of non-dividing but metabolically active cells that secrete a toxic inflammatory “secretome” (SASP: senescence-associated secretory phenotype) — is now recognized as a primary driver of age-related tissue dysfunction and chronic disease. Senescent cells accumulate exponentially with age: a 70-year-old has approximately 30× more senescent cells than a 20-year-old. SASP factors (IL-6, IL-8, MMP-3, TGF-β, VEGF, PAI-1) drive: fibrosis, chronic inflammation, stem cell dysfunction, immune evasion, and paracrine senescence (spreading senescence to neighboring cells). Baker et al. (2011, Nature) demonstrated that clearing senescent cells in progeroid mice extended healthy lifespan by 25% and delayed age-related pathology — a landmark proof-of-concept for senolytic therapy.
Senolytics (drugs that selectively kill senescent cells): Dasatinib + Quercetin (D+Q) is the most studied senolytic combination — Zhu et al. (2015, Aging Cell) demonstrated selective senescent cell elimination in multiple tissues. Kirkland’s Mayo Clinic group published Phase 1 trials showing D+Q reduced senescent cell markers in diabetic kidney disease and IPF patients. Quercetin alone (500–1000mg/day as a senomorphic/partial senolytic) is available as a supplement. Fisetin — a flavonoid in strawberries — demonstrated >50% reduction in senescent cells in mouse models (Yousefzadeh 2018, EBioMedicine) and improved lifespan and physical function. Human fisetin trials are ongoing. Senomorphics (drugs that suppress SASP without killing senescent cells): Rapamycin (mTOR inhibition suppresses SASP), Navitoclax (BCL-2/BCL-xL inhibitor, also apoptotic), and NAD+ precursors (sirtuin activation via NAD+ increases SASP suppression). Current functional medicine approach: quercetin + fisetin as accessible, low-risk natural senolytic/senomorphic supplements alongside lifestyle senostasis optimization.
NAD+ Biology and Sirtuin Activation
NAD+ (nicotinamide adenine dinucleotide) is central to longevity biology: it is the essential cofactor for sirtuins (SIRT1–7, the “longevity proteins”) — NAD+-dependent deacetylases that regulate DNA repair, mitochondrial biogenesis (via PGC-1α), inflammation suppression (via NF-κB deacetylation), and epigenetic maintenance. NAD+ levels decline approximately 50% between ages 20 and 50 in most tissues, impairing sirtuin function and mitochondrial quality control. NAD+ also fuels PARP (poly-ADP ribose polymerase) for DNA repair and CD38/cyclic ADP-ribose for calcium signaling.
Sinclair’s lab at Harvard has demonstrated that restoring NAD+ through NMN supplementation reverses multiple aging hallmarks in mouse models: restored vascular function, reversed muscle atrophy, improved glucose homeostasis, and improved mitochondrial function — with his 2018 Cell paper (Das et al.) showing NMN restored vascular health in old mice to the level of young mice within weeks. Human pharmacokinetic studies confirm NMN (250–500mg/day) raises blood NAD+ by 38–90% (Yoshino 2021, Science). NR (nicotinamide riboside) has similar effects: Martens 2018 (Nature Communications) showed NR 500mg BID raised NAD+ by 51% with improvements in blood pressure and aortic stiffness in older adults. Both NMN and NR effectively raise NAD+ — NMN may have slightly superior cellular uptake due to direct conversion without rate-limiting steps. Practical dosing: NMN 250–500mg/day or NR 300–500mg BID in AM; take with a meal.
Longevity-Promoting Lifestyle Factors: Quantified Evidence
Exercise is the most powerful longevity intervention available without prescription. Mandsager et al. (2018, JAMA Network Open) analyzed cardiorespiratory fitness (CRF) in 122,007 patients and found that the highest CRF quintile had 5× lower all-cause mortality than the lowest — a stronger protective effect than any medication. Each 1-MET increase in VO2max is associated with ~13% reduction in all-cause mortality. For longevity specifically: high-intensity interval training (HIIT) produces 3.4× greater mitochondrial biogenesis response than moderate continuous exercise (Callahan 2021, Cell Metabolism — 12-week HIIT reversed 35 molecular aging biomarkers in 65+ adults). Resistance training preserves muscle mass (sarcopenia — the most potent predictor of frailty and premature death in older adults) and bone mineral density. Zone 2 training (conversational aerobic pace, 60–70% max HR) specifically maximizes fat oxidation capacity and mitochondrial efficiency — Attia and Laursen’s work on Zone 2 as the foundation of longevity training.
Sleep duration and quality: Walker’s (2017, Why We Sleep) synthesis of epidemiological data shows J-shaped mortality curve with nadir at 7–9 hours — both <6 and >9 hours associated with elevated mortality. Sleep restores glymphatic system clearance (Xie 2013, Science) — the brain’s waste removal system that clears amyloid-β, tau, and other neurotoxic metabolites. The glymphatic system operates primarily during NREM deep sleep — a 25% reduction in deep sleep more than doubles amyloid accumulation rate. Social connection: Holt-Lunstad’s meta-analysis (2015, PLOS Medicine — 148 studies, 308,849 participants) found adequate social relationships associated with 50% increased likelihood of survival — an effect size comparable to quitting smoking, exceeding that of exercise or diet. Ikigai (sense of purpose) is associated with significantly reduced all-cause mortality in multiple longitudinal studies.
Frequently Asked Questions
Can epigenetic age testing actually measure how fast you are aging?
Yes — DunedinPACE specifically measures the rate of biological aging (how many biological years per chronological year) rather than a static snapshot of accumulated damage. Individuals with DunedinPACE >1.0 are aging faster than average; <1.0 slower than average. Randomized trial evidence (Fitzgerald 2021, Aging) demonstrated DunedinPACE reversal in response to lifestyle intervention. Commercial testing: TrueAge (TruDiagnostic), Elysium Index, and InsideTracker include epigenetic clock analysis from blood draws. These are increasingly available as clinical tools to personalize longevity interventions and track biological aging response to treatment.
Is rapamycin being used for human longevity?
Rapamycin is used by a growing number of longevity-focused physicians (including Attia, Stanfield, and Gonzalez) in low-dose intermittent regimens (e.g., 5–6mg weekly or 3–5mg 3× monthly — far below transplant immunosuppression doses) based on its animal lifespan extension evidence and emerging human pharmacodynamic data. The Dog Aging Project at University of Washington is conducting the first rigorous RCT of rapamycin in dogs as a model for companion animal and human longevity. Major human longevity trials (PEARL trial — rapamycin in elderly adults) are underway. Current status: rapamycin for longevity is an emerging off-label practice with strong mechanistic rationale and animal evidence, awaiting long-term human RCT outcomes.
What are the most evidence-based supplements for longevity?
Strongest evidence: (1) NMN or NR (250–500mg/day) — restores NAD+ and sirtuin function, with multiple human pharmacokinetic and mechanistic trials confirming efficacy; (2) Quercetin (500–1000mg/day) + Fisetin (100–200mg/day) — senolytic/senomorphic activity reducing SASP and senescent cell burden; (3) Resveratrol/pterostilbene (250–500mg/day) — SIRT1 activation, NRF2, anti-inflammatory; (4) Metformin (500mg–1g/day for non-diabetics — TAME trial ongoing) — AMPK activation, mTOR suppression, epigenetic age reversal documented; (5) Omega-3 (2–4g EPA+DHA) — anti-inflammatory, cardiovascular protection, omega-3 index ≥8% associated with telomere preservation (Farzaneh-Far 2010, JAMA); (6) Vitamin D3 60–80 ng/mL — telomere length preservation, immune surveillance, cancer protection.
Is caloric restriction the most evidence-based longevity intervention?
Caloric restriction (CR) is the most reproducible lifespan-extending intervention across species, but extreme CR (30–40%) produces unacceptable quality-of-life trade-offs in humans. The practical functional medicine equivalent: caloric restriction mimetics that activate the same CR signaling pathways (AMPK, sirtuins, autophagy) without severe food restriction — including intermittent fasting (16:8 or 5:2), time-restricted eating aligned with circadian rhythm, metformin, berberine, resveratrol, NAD+ precursors, and rapamycin. The CALERIE trial (2-year 25% CR in healthy humans) confirmed metabolic improvements but found adherence difficult beyond 1–2 years, supporting mimetic-based approaches for sustainable longevity optimization.
If you’re interested in a comprehensive longevity assessment — including epigenetic age testing, biological age biomarkers, advanced cardiovascular risk profiling, hormonal optimization, and a personalized healthspan extension protocol — call The Private Practice at (810) 206-1402. We offer cutting-edge functional medicine longevity evaluations designed to extend both lifespan and healthspan.
Related Articles
- Leaky Gut & Intestinal Permeability Protocol
- Anti-Inflammatory Diet: Foods & Protocol
- Chronic Stress & Cortisol: What It Does to Your Body